About 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors manufactured by Abbott were recalled in November, because they might give wrong readings.
GlobalData on MSN
Abbott reports positive FreeDM2 study results for CGM
The study was carried out at 24 clinical sites across the UK and included 303 participants.
Nasha is a Managing Editor for CNET, overseeing our sleep and wellness verticals. She is a nutrition, mental health, fitness and sleep science enthusiast. Her passion for mindful and holistic ...
Abbott (NYSE:ABT) today announced results from a trial demonstrating better glucose outcomes for users of continuous glucose monitors (CGMs).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results